Atlas FDA

VENTANA ALK (D5F3) CDX ASSAY

FDA premarket approval P140025/S003 · decided 2016-10-21

Approval details

PMA number
P140025
Supplement
S003
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
VENTANA ALK (D5F3) CDX ASSAY
Generic name
Immunohistochemistry assay, antibody, anaplastic lymphoma kinase
Applicant
Ventana Medical Systems, Inc.
Date received
2016-03-22
Decision date
2016-10-21
Days to decision
213 days
Decision code
APPR
Product code
PKW
Advisory committee
Pathology
Expedited review
No
Location
Tucson, AZ
Statement
Approval for adding the BenchMark ULTRA instrument to the intended use and labeling for the VENTANA ALK (D5F3) CDx Assay

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Roche Digital Pathology Dx (K242783)Ventana Medical Systems, Inc.2024-12-17
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail (08507023001) (DEN240025)Ventana Medical Systems, Inc.2024-12-05
Roche Digital Pathology Dx (VENTANA DP 200) (K232879)Ventana Medical Systems, Inc.2024-06-14
CINtec Histology (K212176)Ventana Medical Systems, Inc.2021-12-10
VENTANA CD30 (Ber-H2) RxDx Assay (K172471)Ventana Medical Systems, Inc.2018-05-08
CINtec Histology (50 tests), CINtec Histology (250 tests) (DEN160019)Ventana Medical Systems, Inc.2017-03-04
Virtuoso System for IHC PR (1E2) using iScan HT (K142965)Ventana Medical Systems, Inc.2015-07-16
VIRTUOSO SYSTEM FOR IHC ER (SP1) WITH BENCHMARK ULTRA STAINER (K140465)Ventana Medical Systems, Inc.2014-03-20